Fig. 2

Change from baseline in MMD by treatment and visit (Full analysis set). Adjusted LSM and 95% CIs from the primary analysis model are presented. Note: The primary efficacy endpoint (change from baseline in MMD) was analysed using a generalised linear mixed effects repeated measures model based on observed monthly data during the treatment period. CI, confidence interval; LSM, least-squares means; MMD, monthly migraine days